Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this four-arm randomized controlled study is to determine whether eliminating glucocorticoids (GC) replacement in perioperative period in surgical patients with sellar lesion could result in similar or better outcomes comparing to traditional replacement therapy, regarding postoperative recovery of pituitary function and other postoperative complications (infection, pain, quality of life, recurrence). Surgical patients of our center with MRI-confirmed diagnosis of sellar lesion will be enrolled, insulin tolerance test (ITT) will be performed for assessment of the pituitary function at enrollment. Patients with normal pituitary function will be randomized into non-GC replacement group (group A) and low-dose GC replacement group (group B), while patients with impaired pituitary function will be randomized into low-dose GC replacement group (group C) and high-dose GC replacement group (group D). The primary outcome is the hypothalamic-pituitary-adrenal (HPA) -axis function of the patients, evaluated by plasma cortisol and adrenocorticotropic hormone (ACTH) levels. The secondary outcomes include the hypothalamic-pituitary-thyroid (HPT) axis function (TSH, thyroid-stimulating hormone, free T3, free T4), postoperative water-electrolyte balance, infection, recurrence and health-related quality of life.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A. Normal function, non-GC replacement | No Intervention | No glucocorticoid replacement will be given perioperatively. | |
| B. Normal function, low-dose GC | Active Comparator | Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6; |
|
| C. Impaired function, low-dose GC | Active Comparator | Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6; |
|
| D. Impaired function, high-dose GC | Active Comparator | Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hydrocortisone | Drug | used intravenously |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline plasma cortisol level | Plasma cortisol at 8:00, 16:00, 24:00 respectively | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Change from baseline plasma ACTH level | ACTH at 8:00; | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Change from baseline 24-hour urine free cortisol | 24-hour urine free cortisol | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Change from baseline insulin tolerance test result | insulin tolerance test result | 7, 30, 90 days post-op |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline plasma TSH level | plasma TSH level | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Sodium, potassium concentration in the blood and urine | Concentration of sodium, potassium in the blood and urine |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Senlin Yin, M.D. | Contact | +86 13072808795 | enforest@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Shu Jiang, M.D. | West China Hospital, Sichuan University, Chengdu, Sichuan, PR China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| West China Hospital, Sichuan University | Recruiting | Chengdu | Sichuan | 610041 | China |
Not provided
| ID | Term |
|---|---|
| D010911 | Pituitary Neoplasms |
| D003397 | Craniopharyngioma |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D007029 | Hypothalamic Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D006854 | Hydrocortisone |
| D011241 | Prednisone |
| ID | Term |
|---|---|
| D011282 | Pregnenediones |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Prednisone | Drug | used as tablet form |
|
| Daily post-op,for the duration of hospital stay, an expected average of 7 days |
| Number of patients with postoperative infection | Routine blood test, body temperature fluctuation, cerebrospinal fluid test if necessary. | For the duration of hospital stay, an expected average of 7 days |
| Change from baseline health-related quality of life | The 15-Dimensions measure of health-related quality of life | 7, 30, 90 days post-op |
| Number of patients with recurred tumor | Enhanced MRI scan of the sellar region. | 3,6,12 months after surgery |
| Change from baseline plasma free T3 level | plasma free T3 level | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Change from baseline plasma free T4 level | plasma free T4 level | 1, 3, 5, 7, 30, 90, 180, 360 days post-op |
| Urine output | 24-hour urine output | Daily post-op,for the duration of hospital stay, an expected average of 7 days |
| D015173 |
| Supratentorial Neoplasms |
| D001932 | Brain Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D007027 | Hypothalamic Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009380 | Neoplasms, Nerve Tissue |
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D015062 | 11-Hydroxycorticosteroids |
| D006889 | Hydroxycorticosteroids |
| D000305 | Adrenal Cortex Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D015065 | 17-Hydroxycorticosteroids |
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |